Payment overview · 2025
General Payments
$208.98
11 reported records · 7 companies
Healthcare provider profile · identity verified
Brian A Baxter, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SANDUSKY, OH · NPI 1649220450
Verified facts
What the public records show
CMS Open Payments records show Brian A Baxter, D.O. received $208.98 in general payments during 2025 across 11 reported records.
Exact Sciences Corporation accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.25 | 33.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.68 | 16.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.69 | 14.7% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $28.45 | 13.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.96 | 8.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.13 | 7.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.82 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.98 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $69.25 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 91 |
| Lisinopril | Lisinopril | 174 | 54 |
| Metformin Hcl | Metformin Hcl | 168 | 56 |
| Omeprazole | Omeprazole | 162 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 51 |
| Furosemide | Furosemide | 145 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 43 |
| Gabapentin | Gabapentin | 132 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 36 |
| Losartan Potassium | Losartan Potassium | 103 | 33 |
| Tramadol Hcl | Tramadol Hcl | 101 | 30 |
| Alprazolam | Alprazolam | 97 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 30 |
| Allopurinol | Allopurinol | 87 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 85 | 26 |
| Potassium Chloride | Potassium Chloride | 85 | 33 |
| Simvastatin | Simvastatin | 83 | 22 |
| Prednisone | Prednisone | 80 | 63 |
| Eliquis | Apixaban | 77 | 20 |
| Glimepiride | Glimepiride | 77 | 28 |
| Montelukast Sodium | Montelukast Sodium | 71 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 21 |
| Bupropion Xl | Bupropion Hcl | 56 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 21 |
| Jardiance | Empagliflozin | 55 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 17 |
| Fluconazole | Fluconazole | 51 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Meloxicam | Meloxicam | 49 | 22 |
| Spironolactone | Spironolactone | 49 | 18 |
| Azithromycin | Azithromycin | 46 | 38 |
| Ozempic | Semaglutide | 46 | suppressed |
| Xarelto | Rivaroxaban | 45 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 15 |
| Celecoxib | Celecoxib | 41 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 40 | suppressed |
| Carvedilol | Carvedilol | 40 | 16 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 12 |
| Donepezil Hcl | Donepezil Hcl | 37 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | 12 |
| Lorazepam | Lorazepam | 35 | 11 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 15 |
| Ezetimibe | Ezetimibe | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Finasteride | Finasteride | 31 | 11 |
| Ibuprofen | Ibuprofen | 31 | 14 |
| Naproxen | Naproxen | 31 | 13 |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 24 |
| Valsartan | Valsartan | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | 11 |
| Cephalexin | Cephalexin | 26 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | 11 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.98 · 11 records | Exact Sciences Corporation | AIRSUPRA, APRETUDE, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error